SCHEMBL20249244

SCHEMBL20249244

CC(C)(C)c1ccc(N2CC3(CCNCC3)C2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.50
ALDH1A1 P00352 9/20 0.49
CYP2D6 P10635 9/20 0.49
HSD17B10 Q99714 7/20 0.49
CYP1A2 P05177 6/20 0.49
USP2 O75604 6/20 0.49
CYP3A4 P08684 5/20 0.49
HPGD P15428 4/20 0.49
TP53 P04637 3/20 0.49
MAPK1 P28482 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HIF1A Q16665 1/20 0.43
CDK4 P11802 2/20 0.42
CCND1 P24385 2/20 0.42
CDK6 Q00534 2/20 0.42
CYP2C19 P33261 4/20 0.40
CYP2C9 P11712 3/20 0.40
CHRNB2 P17787 4/20 0.38
CHRNA4 P43681 4/20 0.38
CHRNB4 P30926 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20249248 0.92 TSHR (0.41) TSHRALDH1A1CYP2D6HSD17B10CYP1A2
SCHEMBL20249239 0.87 CYP3A4 (0.33) TSHRALDH1A1CYP2D6HSD17B10CYP1A2
SCHEMBL20249243 0.85 CDK4 (0.40) TSHRALDH1A1CYP2D6HSD17B10CYP1A2
SCHEMBL20249246 0.84 ALDH1A1 (0.45) TSHRALDH1A1CYP2D6HSD17B10CYP1A2
SCHEMBL20249245 0.81 CHRNB2 (0.51) CDK4CCND1CHRNB2CHRNA4CHRNB4
SCHEMBL18291588 0.81 TSHR (0.54) TSHRALDH1A1CYP2D6HSD17B10CYP1A2
SCHEMBL12145921 0.80 CHRNB2 (0.58) ALDH1A1CDK4CCND1CHRNB2CHRNA4
SCHEMBL20249240 0.78 CHRNB2 (0.46) CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL20037703 0.78 TSHR (0.54) TSHRALDH1A1CYP2D6HSD17B10CYP1A2
SCHEMBL20255479 0.78 TSHR (0.54) TSHRALDH1A1CYP2D6HSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 TSHR 2977/4885ALDH1A1 944/4885CYP2D6 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.